577 related articles for article (PubMed ID: 29780393)
1. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
3. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
4. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
5. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.
Khaznadar Z; Henry G; Setterblad N; Agaugue S; Raffoux E; Boissel N; Dombret H; Toubert A; Dulphy N
Eur J Immunol; 2014 Oct; 44(10):3068-80. PubMed ID: 25041786
[TBL] [Abstract][Full Text] [Related]
8. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
9. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
Fauriat C; Just-Landi S; Mallet F; Arnoulet C; Sainty D; Olive D; Costello RT
Blood; 2007 Jan; 109(1):323-30. PubMed ID: 16940427
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
11. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
13. IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.
Lopez-Millan B; Diaz de la Guardia R; Roca-Ho H; Anguita E; Islam ABMMK; Romero-Moya D; Prieto C; Gutierrez-Agüera F; Bejarano-Garcia JA; Perez-Simon JA; Costales P; Rovira M; Marín P; Menendez S; Iglesias M; Fuster JL; Urbano-Ispizua A; Anjos-Afonso F; Bueno C; Menendez P
Oncoimmunology; 2018; 7(9):e1477460. PubMed ID: 30228947
[TBL] [Abstract][Full Text] [Related]
14. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
[TBL] [Abstract][Full Text] [Related]
15. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
Ingram W; Chan L; Guven H; Darling D; Kordasti S; Hardwick N; Barber L; Mufti GJ; Farzaneh F
Br J Haematol; 2009 Jun; 145(6):749-60. PubMed ID: 19388935
[TBL] [Abstract][Full Text] [Related]
16. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
[TBL] [Abstract][Full Text] [Related]
18. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
20. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
